Full-Time

Medical Director

Medical Affairs-Dermatology

Posted on 5/5/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$275.2k - $372.4k/yr

Senior, Expert

Tarrytown, NY, USA

Relocation benefits may be offered.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Regeneron Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Medical (MD / MBBS or equivalent)
  • >7 years of medical affairs or clinical development experience
  • Solid background and experience in drug development and life-cycle development of immunology related products
  • Dermatology experience is required
Responsibilities
  • Developing and leads all aspects of implementation of medical strategy and tactics, including scientific communications and publications, annual medical planning, field communications, and collaborations within the healthcare community
  • Applying therapeutic/disease area expertise and business understanding to address current and future medical needs in clinical practice with medically appropriate use of investigational medicines
  • Overseeing and provides hands on support in management, generation and dissemination of clinical and non-clinical data and results in high quality publications
  • Acting as standing or ad-hoc member for various teams; provides scientific/medical perspectives to the global and US strategic and medical organizations
  • Co-leads the formation, refinement and execution of a robust Phase 3b/4 plan
  • Supporting the design, conduct, oversight, analysis and reporting of Medical Affairs clinical trials
  • Ensuring timely submission and delivery of high-quality clinical trial documentation, implementation and execution
  • Continuing to develop and cultivate long-term strategic partnerships with clinical experts, societies, collaborative groups, advocacy groups, and other external collaborators representing
  • Prioritizing support of investigator-initiated studies and serves as a key member of internal Scientific Review Committees
  • Ensuring accuracy of training material for scientific and product information
  • Coordinating medical review and approval of promotional materials
  • Ensuring goals and objectives are met and projects completed on time and within budget
  • Is responsible for optimal medical affairs resource allocation across the spectrum of a product’s life cycle
  • Oversees development and forecasting of project budgets across assets
  • Champions high standards of compliance, ethics and patient safety, putting patients at the center of all actions
  • Performs medical monitoring of post-registrational trials and is the signatory of documents related to interpretation of patient level data where necessary
  • Interacts internally and externally with senior management and functional heads
  • Represents Medical Affairs on the Strategic Product Team
  • Works in a goal/objective oriented manner within formalized process to plan and implement annual goals in alignment with the corporate annual goals and core business strategy
  • Potential to supervise Medical Directors and/or Associate Director
Desired Qualifications
  • Any alliance related setting experience is preferred
  • Demonstrated experience leading technical and business discussions internally and externally and explain scientific/medical concepts to all levels
  • Ability to cultivate and maintain relationships with leading medical/scientific experts in the relevant fields
  • Ability to establish trust through the consistent demonstration of scientific expertise and follow-through on requests from key opinion leaders
  • Strong leadership and management skills
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron stands out from competitors by focusing on strategic partnerships that allow for shared development costs and profits. Its goal is to improve patient outcomes through effective treatments while ensuring compliance with safety and efficacy standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's approval for CSU opens a new market segment in the US.
  • $3.6 billion Tarrytown expansion boosts research capabilities and local economy.
  • Partnership with Fujifilm enhances manufacturing capacity for biologics.

What critics are saying

  • Tarrytown expansion poses financial risk if ROI is not realized.
  • Dependency on Fujifilm for manufacturing may lead to operational risks.
  • Regulatory setbacks, like Dupixent's initial rejection, can impact market entry.

What makes Regeneron Pharmaceuticals unique

  • Regeneron specializes in life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug development.
  • Regeneron collaborates with academic and research institutions to enhance R&D efforts.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

Ophthalmology Times
Apr 28th, 2025
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR

Regeneron has announced the upcoming presentation of 27 abstracts, including 8 oral presentations on aflibercept injection 8 mg (EYLEA HD) in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Pharma Journalist
Apr 24th, 2025
Regeneron Invests in Expanding Biologic Medicine Manufacturing

Regeneron continues to invest heavily in its New York State operations, where an approximately $3.6 billion expansion of its Tarrytown campus is underway, creating 1,000 full-time, high-skill jobs and expanding research, preclinical manufacturing and support facilities.

PharmiWeb
Apr 24th, 2025
Dupixent Approved In The Us As The First New Targeted Therapy In Over A Decade For Chronic Spontaneous Urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks

Texas Border Business
Apr 23rd, 2025
America's Manufacturing Power Surges as Global Giants Invest Billions

Additionally, Regeneron is investing approximately $3.6 billion to expand its Tarrytown, New York facility, aiming to double its manufacturing capabilities nearly.

Pharmaceutical Technology
Apr 22nd, 2025
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity.

INACTIVE